Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,248 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.
Gilbert L, Oaknin A, Matulonis UA, Mantia-Smaldone GM, Lim PC, Castro CM, Provencher D, Memarzadeh S, Method M, Wang J, Moore KN, O'Malley DM. Gilbert L, et al. Gynecol Oncol. 2023 Mar;170:241-247. doi: 10.1016/j.ygyno.2023.01.020. Epub 2023 Feb 1. Gynecol Oncol. 2023. PMID: 36736157 Free article.
Insulin-like growth factor-I and risk of high-grade cervical intraepithelial neoplasia.
Schaffer A, Koushik A, Trottier H, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Pollak MN, Franco EL; Biomarkers of Cervical Cancer Risk Study Team. Schaffer A, et al. Among authors: gilbert l. Cancer Epidemiol Biomarkers Prev. 2007 Apr;16(4):716-22. doi: 10.1158/1055-9965.EPI-06-0924. Cancer Epidemiol Biomarkers Prev. 2007. PMID: 17416762
Selected class I and class II HLA alleles and haplotypes and risk of high-grade cervical intraepithelial neoplasia.
Ades S, Koushik A, Duarte-Franco E, Mansour N, Arseneau J, Provencher D, Gilbert L, Gotlieb W, Ferenczy A, Coutlée F, Roger M, Franco EL; Biomarkers of Cervical Cancer Risk (BCCR) Study Team. Ades S, et al. Among authors: gilbert l. Int J Cancer. 2008 Jun 15;122(12):2820-6. doi: 10.1002/ijc.23459. Int J Cancer. 2008. PMID: 18351579 Free article.
The Meaning-Making intervention (MMi) appears to increase meaning in life in advanced ovarian cancer: a randomized controlled pilot study.
Henry M, Cohen SR, Lee V, Sauthier P, Provencher D, Drouin P, Gauthier P, Gotlieb W, Lau S, Drummond N, Gilbert L, Stanimir G, Sturgeon J, Chasen M, Mitchell J, Huang LN, Ferland MK, Mayo N. Henry M, et al. Among authors: gilbert l. Psychooncology. 2010 Dec;19(12):1340-7. doi: 10.1002/pon.1764. Psychooncology. 2010. PMID: 20878857 Clinical Trial.
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.
Mirza MR, Monk BJ, Herrstedt J, Oza AM, Mahner S, Redondo A, Fabbro M, Ledermann JA, Lorusso D, Vergote I, Ben-Baruch NE, Marth C, Mądry R, Christensen RD, Berek JS, Dørum A, Tinker AV, du Bois A, González-Martín A, Follana P, Benigno B, Rosenberg P, Gilbert L, Rimel BJ, Buscema J, Balser JP, Agarwal S, Matulonis UA; ENGOT-OV16/NOVA Investigators. Mirza MR, et al. Among authors: gilbert l. N Engl J Med. 2016 Dec 1;375(22):2154-2164. doi: 10.1056/NEJMoa1611310. Epub 2016 Oct 7. N Engl J Med. 2016. PMID: 27717299 Free article. Clinical Trial.
Hormonal and reproductive factors and the risk of ovarian cancer.
Koushik A, Grundy A, Abrahamowicz M, Arseneau J, Gilbert L, Gotlieb WH, Lacaille J, Mes-Masson AM, Parent MÉ, Provencher DM, Richardson L, Siemiatycki J. Koushik A, et al. Among authors: gilbert l. Cancer Causes Control. 2017 May;28(5):393-403. doi: 10.1007/s10552-016-0848-9. Epub 2017 Jan 19. Cancer Causes Control. 2017. PMID: 28102526
Evaluation of Prophylactic Corticosteroid Eye Drop Use in the Management of Corneal Abnormalities Induced by the Antibody-Drug Conjugate Mirvetuximab Soravtansine.
Matulonis UA, Birrer MJ, O'Malley DM, Moore KN, Konner J, Gilbert L, Martin LP, Bauer TM, Oza AM, Malek K, Pinkas J, Kim SK. Matulonis UA, et al. Among authors: gilbert l. Clin Cancer Res. 2019 Mar 15;25(6):1727-1736. doi: 10.1158/1078-0432.CCR-18-2474. Epub 2018 Nov 9. Clin Cancer Res. 2019. PMID: 30413525 Clinical Trial.
Shift Work Patterns, Chronotype, and Epithelial Ovarian Cancer Risk.
Leung L, Grundy A, Siemiatycki J, Arseneau J, Gilbert L, Gotlieb WH, Provencher DM, Aronson KJ, Koushik A. Leung L, et al. Among authors: gilbert l. Cancer Epidemiol Biomarkers Prev. 2019 May;28(5):987-995. doi: 10.1158/1055-9965.EPI-18-1112. Epub 2019 Mar 6. Cancer Epidemiol Biomarkers Prev. 2019. PMID: 30842128
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Del Campo JM, Matulonis UA, Malander S, Provencher D, Mahner S, Follana P, Waters J, Berek JS, Woie K, Oza AM, Canzler U, Gil-Martin M, Lesoin A, Monk BJ, Lund B, Gilbert L, Wenham RM, Benigno B, Arora S, Hazard SJ, Mirza MR. Del Campo JM, et al. Among authors: gilbert l. J Clin Oncol. 2019 Nov 10;37(32):2968-2973. doi: 10.1200/JCO.18.02238. Epub 2019 Jun 7. J Clin Oncol. 2019. PMID: 31173551 Free PMC article. Clinical Trial.
1,248 results